AU2001265844B2 - A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease - Google Patents

A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease Download PDF

Info

Publication number
AU2001265844B2
AU2001265844B2 AU2001265844A AU2001265844A AU2001265844B2 AU 2001265844 B2 AU2001265844 B2 AU 2001265844B2 AU 2001265844 A AU2001265844 A AU 2001265844A AU 2001265844 A AU2001265844 A AU 2001265844A AU 2001265844 B2 AU2001265844 B2 AU 2001265844B2
Authority
AU
Australia
Prior art keywords
day
galantamine
dosage
dose
followed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001265844A
Other languages
English (en)
Other versions
AU2001265844A1 (en
Inventor
Wim Louis Julien Parys
Michael Pontecorvo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2001265844A1 publication Critical patent/AU2001265844A1/en
Application granted granted Critical
Publication of AU2001265844B2 publication Critical patent/AU2001265844B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2001265844A 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease Ceased AU2001265844B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
US60/194,259 2000-04-03
PCT/EP2001/003553 WO2001074339A2 (fr) 2000-04-03 2001-03-28 Utilisation de la galantamine dans le traitement du comportement neuropsychiatrique associe a la maladie d'alzheimer

Publications (2)

Publication Number Publication Date
AU2001265844A1 AU2001265844A1 (en) 2002-01-03
AU2001265844B2 true AU2001265844B2 (en) 2005-04-14

Family

ID=22716898

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001265844A Ceased AU2001265844B2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
AU6584401A Pending AU6584401A (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU6584401A Pending AU6584401A (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Country Status (20)

Country Link
EP (1) EP1272192A2 (fr)
JP (1) JP2003528913A (fr)
KR (1) KR20020086911A (fr)
CN (1) CN1430514A (fr)
AU (2) AU2001265844B2 (fr)
BG (1) BG107093A (fr)
BR (1) BR0109770A (fr)
CA (1) CA2310926C (fr)
CZ (1) CZ20023543A3 (fr)
EE (1) EE200200554A (fr)
HR (1) HRP20020778A2 (fr)
HU (1) HUP0300566A3 (fr)
IL (1) IL152061A0 (fr)
MX (1) MXPA02009777A (fr)
NO (1) NO20024746L (fr)
PL (1) PL361272A1 (fr)
RU (1) RU2002129298A (fr)
SK (1) SK15422002A3 (fr)
WO (1) WO2001074339A2 (fr)
ZA (1) ZA200207935B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
ES2293287T3 (es) * 2003-07-25 2008-03-16 F. Hoffmann-La Roche Ag Combinacion de antagonista de mglur2 y de inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos.
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
JP5647099B2 (ja) 2008-03-27 2014-12-24 チェイス・ファーマスーティカルズ・コーポレーション 認知症を治療するための使用及び組成物
WO2013160728A1 (fr) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Composés à double ciblage pour le traitement de la maladie d'alzheimer
BG66818B1 (bg) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Състав на екстракт от hippeastrum papilio за производство на лекарствени средства и хранителни добавки
WO2016187339A1 (fr) * 2015-05-18 2016-11-24 Synaptec Development Llc Clairance de galantamine d'amyloides
WO2023036105A1 (fr) * 2021-09-09 2023-03-16 上海日馨医药科技股份有限公司 Méthode de traitement d'une maladie neurodégénérative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (de) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Verfahren zur Isolierung von Galanthamin
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
US7939522B1 (en) 1998-11-23 2011-05-10 Bonnie M Davis Dosage formulations for acetylcholinesterase inhibitors
AU775914B2 (en) * 1998-12-24 2004-08-19 Janssen Pharmaceutica N.V. Controlled release galantamine composition
CA2310950C (fr) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. Posologie de galantamine efficace qui reduit les effets secondaires
CA2310990A1 (fr) * 2000-04-03 2000-10-09 Michael Pontecorvo Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie

Also Published As

Publication number Publication date
ZA200207935B (en) 2004-01-30
EP1272192A2 (fr) 2003-01-08
NO20024746L (no) 2002-11-28
MXPA02009777A (es) 2003-03-27
KR20020086911A (ko) 2002-11-20
WO2001074339A2 (fr) 2001-10-11
WO2001074339A3 (fr) 2002-09-12
RU2002129298A (ru) 2004-03-27
CN1430514A (zh) 2003-07-16
HRP20020778A2 (en) 2004-04-30
PL361272A1 (en) 2004-10-04
NO20024746D0 (no) 2002-10-02
SK15422002A3 (sk) 2003-04-01
HUP0300566A3 (en) 2004-10-28
BR0109770A (pt) 2003-02-04
BG107093A (bg) 2003-06-30
JP2003528913A (ja) 2003-09-30
CA2310926C (fr) 2002-10-15
IL152061A0 (en) 2003-05-29
EE200200554A (et) 2004-04-15
CZ20023543A3 (cs) 2003-03-12
CA2310926A1 (fr) 2000-10-04
AU6584401A (en) 2001-10-15
HUP0300566A2 (hu) 2003-06-28

Similar Documents

Publication Publication Date Title
CA2310950C (fr) Posologie de galantamine efficace qui reduit les effets secondaires
EA012325B1 (ru) Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
AU2001265844B2 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
Butala et al. Optimizing topical management of atopic dermatitis
US20220184074A1 (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
AU2001265844A1 (en) A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
JPH0667842B2 (ja) 基本的うつ病を軽減するためのうつ病治療剤
Bachert et al. Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis
US20060172993A1 (en) Use of galantamine for the treatment of neuropsychiatric behaviour associated with Alzheimer's disease
Stanaland Treatment of patients with chronic idiopathic urticaria
US11389420B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
WO2020014072A1 (fr) Association pharmaceutique de néostigmine pour le traitement de la myasthénie grave
RU2818678C2 (ru) Способы лечения хронической спонтанной крапивницы с применением ингибитора тирозинкиназы брутона
US12023315B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
US11752141B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
US20200000756A1 (en) Neostigmine combination and compositions
Flowers et al. Antihistamines.
US20230364060A1 (en) Methods and compositions for treating glucocorticoid excess
Mao et al. Treatment of Parkinson’s disease with piribedil: Suggestions for clinical practices
Panas et al. Belladonna alkaloids and phenobarbital use in the treatment of irritable bowel syndrome: a review
Whitworth et al. Clinical trial of an orally administered converting enzyme inhibitor (Captopril)
CA2310990A1 (fr) Utilisation de la galantamine pour le traitement de la maladie d'alzheimer; ciblage de la cause sous-jacente de la maladie
WO2021055576A1 (fr) Combinaison de modafinil et d'une ampakine pour améliorer la cognition
Zonneveld Psoriasis. Present therapies and new developments

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired